glp-1 resistance glp 1 agonists in pediatric obesity: an integrative perspective on cell signaling, development glp-1_analogs [TUSOM | Pharmwiki]

And, the food industry seems to do their best to sabotage us at every opportunity

For type 2 diabetes management , licensed GLP-1 medications include: Exenatide (Byetta, Bydureon) available as twice-daily or once-weekly formulations Liraglutide (Victoza) administered once daily Dulaglutide (Trulicity) given once weekly Semaglutide (Ozempic) administered once weekly as an injection Semaglutide (Rybelsus) taken orally once daily (for type 2 diabetes only, not licensed for weight management) For weight management in adults with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with weight-related comorbidities, two medications hold specific licences: Liraglutide 3.0 mg (Saxenda) once-daily subcutaneous injection Semaglutide 2.4 mg (Wegovy) once-weekly subcutaneous injection Access to these medications through the NHS is governed by NICE guidance

Khani M, Afsahi R, Nasab AE, et al

Gupta M, Petti TA

Semaglutide is a peptide that must be injected once a week

Also, check with your primary care doctor first for an accurate diagnosis